Authors: Stephanie L. Foster, Courtney Woolsey, Viktoriya Borisevich, Krystle N. Agans, Abhishek N. Prasad, Joan B. Geisbert, Natalie S. Dobias, Karla A. Fenton, Robert W. Cross, Thomas W. Geisbert, Daniel J. Dee
Year: 2024
Journal: Not specified in the text
DOI: 10.xxxx/xxxxx or null (not specified in the text)
PMID: PMID or null (not specified in the text)
Summary#
The paper discusses a study using a recombinant vesicular stomatitis virus (rVSV) vaccine to protect nonhuman primates from lethal Nipah virus disease, with protection observed in monkeys vaccinated 7 days prior to NiV exposure and 67% of animals vaccinated 3 days before challenge.
Key Findings#
- Recombinant VSV-ΔGNiVBG vaccine protects nonhuman primates against lethal Nipah virus disease
- Protection correlated with natural killer cell and cytotoxic T cell transcriptional signatures
Methodology#
- Study Type: Experimental/Vaccine trial
- Sample Size: African green monkeys (number not specified)
- Geographic Focus: Not specified in the text
- Time Period: 3 or 7 days after vaccination and NiV challenge
Topics#
Virology, Vaccine development
Relevance#
The study demonstrates the potential utility of rVSV-based vaccines in rapidly protecting humans against Nipah virus infection, which could be crucial for controlling outbreaks